Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex Enbrel Building Sales Force For Psoriatic Arthritis Approval

Executive Summary

Immunex is building its first internal Enbrel sales force in preparation for etanercept's sBLA approval for psoriatic arthritis, Commercial Operations General Manager Mark Booth announced Aug. 20 during the company's R&D update in Seattle.
Advertisement

Related Content

Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Amgen Kineret Has 12-Month Head Start Before Increase In Enbrel Supply
Amgen Kineret Has 12-Month Head Start Before Increase In Enbrel Supply
Immunex Enbrel Psoriatic Arthritis Advisory Cmte. Expected In December
Immunex Enbrel Psoriatic Arthritis Advisory Cmte. Expected In December
Advertisement
UsernamePublicRestriction

Register

PS038402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel